Takeda Makes Financial Moves To Trim Cash Flow While Adding R&D
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical is suspending its three-year practice of buying back its own stock as it tightens its belt to increase research-and-development spending at the same time it continues to pay dividends. The 6 percent R&D budget increase is considered by Takeda as critical to plans to develop badly needed new drugs to replace expiring patents. Takeda has cut expenses elsewhere and plans not to increase its dividend to stockholders this fiscal year. The halt in stock buybacks also is intended to maintain its cash reserve. (Click here for more - a subscription may be required
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.